Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Gross Margin (2016 - 2025)

Historic Gross Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 38.37%.

  • Lifecore Biomedical, Inc. \De\'s Gross Margin fell 72200.0% to 38.37% in Q2 2025 from the same period last year, while for May 2025 it was 31.27%, marking a year-over-year decrease of 13600.0%. This contributed to the annual value of 31.27% for FY2025, which is 13600.0% down from last year.
  • Lifecore Biomedical, Inc. \De\'s Gross Margin amounted to 38.37% in Q2 2025, which was down 72200.0% from 28.01% recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Gross Margin registered a high of 45.59% during Q2 2024, and its lowest value of 11.12% during Q3 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median Gross Margin value was 32.74% (recorded in 2023), while the average stood at 31.39%.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Gross Margin surged by 262000bps in 2021 and then tumbled by -187800bps in 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Gross Margin (Quarter) stood at 44.76% in 2021, then plummeted by -42bps to 25.97% in 2022, then increased by 27bps to 33.02% in 2023, then grew by 3bps to 34.04% in 2024, then increased by 13bps to 38.37% in 2025.
  • Its Gross Margin stands at 38.37% for Q2 2025, versus 28.01% for Q1 2025 and 34.04% for Q4 2024.